During the last session, Nektar Therapeutics (NASDAQ:NKTR)’s traded shares were 1.05 million, with the beta value of the company hitting 0.76. At the end of the trading day, the stock’s price was $1.32, reflecting an intraday loss of -4.35% or -$0.06. The 52-week high for the NKTR share is $1.75, that puts it down -32.58 from that peak though still a striking 68.94% gain since the share price plummeted to a 52-week low of $0.41. The company’s market capitalization is $242.38M, and the average trade volume was 2.51 million shares over the past three months.
Nektar Therapeutics (NASDAQ:NKTR) trade information
The stock plummet -4.35% in intraday trading to $1.32, hitting a weekly high. The stock’s 5-day price performance is 0.00%, and it has moved by 46.67% in 30 days. Based on these gigs, the overall price performance for the year is 70.06%.
Nektar Therapeutics (NKTR) estimates and forecasts
Statistics show that Nektar Therapeutics has outperformed its competitors in share price, compared to the industry in which it operates. Nektar Therapeutics (NKTR) shares have gone up 173.75% during the last six months, with a year-to-date growth rate more than the industry average at 32.41% against 10.20. In the rating firms’ projections, revenue will decrease -25.10% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 15.34M as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 15.34M by the end of current fiscal year.
While earnings are projected to return 38.97% in 2024, the next five years will return -7.30% per annum.
NKTR Dividends
Nektar Therapeutics is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
